Jones becomes Meditech's lead physician

Jeff Byers | | Health Exec | Economics
Steven Jones, MD, family practice physician, will join Meditech as the company's lead physician for electronic health record (EHR) development efforts, as well as across multiple clinical projects.

Throughout his tenure at Exeter Hospital in Exeter, N.H., Jones was an informatics physician in addition to his specialties in obstetrics and gynecology, and family medicine, according to Meditech, of Westwood, Mass. Jones has been a member of Meditech's physician advisory committee.

Jones was involved in the implementation and ongoing development of the outpatient EMR solution at Lamprey Healthcare, a network of New Hampshire clinics. The company's EMR project received the HIMSS Davies Award of Excellence in 2008.

Jeff Byers

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.